-- Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) reported its third-quarter 2019 adjusted earnings of $6.67 per share versus $6.36 per share expected. --
Regeneron Pharmaceuticals (NASDAQ: REGN): Q3 2019 Earnings Snapshot
Categories
Biotechnology
Allergan (AGN) Q3 earnings preview: Patent issues, AbbVie deal in focus
After securing shareholders' approval for the takeover deal with AbbVie (ABBV), Allergan (NYSE: AGN) will be publishing its third-quarter results on November
Immunogen Inc (NASDAQ:IMGN) Q3 2019 Earnings Call Transcript
Immunogen Inc (IMGN) Q3 2019 earnings call dated Nov 1, 2019 Corporate Participants: Courtney O'Konek -- Senior Director of Corporate Communications and Investor Relations
Biogen (BIIB) Q3 profit rises 7% on spinal muscular atrophy drug addition
Biogen Inc. (NASDAQ: BIIB) reported a 7% increase in earnings for the third quarter of 2019 as spinal muscular atrophy drug Spinraza
Biogen (BIIB) earnings preview: Will stock bounce back after Q3 report?
The market value of pharma giant Biogen, Inc. (NASDAQ: BIIB) declined by a third in March when the stock suffered a heavy
Pfenex shares shoot up on getting FDA approval for its osteoporosis drug
Shares of Pfenex (NYSE: PFNX) jumped over 15% in today's pre-market trading session as the clinical-stage biotech company received approval from the
Two zero-revenue biotech stocks debut in a shaky IPO market
The IPO market has recently been pretty unwelcoming, with some of the popular firms going dud right after their debut. Endeavor Group
Will Zynerba Zygel trial be extended amid safety warning?
Zynerba Pharmaceuticals (NASDAQ: ZYNE) stock retreated on Wednesday after serious adverse events in phase 2 clinical trial of transdermal cannabidiol gel, Zygel.
Alexion Pharmaceuticals could still be a valuable addition to your portfolio
Biopharmaceutical firm Alexion Pharmaceuticals (NASDAQ: ALXN) has been going through a volatile phase lately. The company was expected to be the takeover
Lundbeck to acquire Alder BioPharmaceuticals for $1.95 billion; Alder stock hits new 52-week high
Denmark-based biopharma company Lundbeck announced today that it will acquire Alder BioPharmaceuticals (NASDAQ: ALDR) for $1.95 billion. Alder stock, which reached a
Catalyst Pharmaceuticals stock soars to record high
Catalyst Pharmaceuticals (NASDAQ: CPRX) stock soared to a record high of $7.67 on Wednesday as phase 3 trial results date is nearing
Earnings preview: Market has low expectations ahead of Advaxis’ Q3 report
Advaxis (NASDAQ: ADXS), a late-stage biotech firm, is one of the worst-performing healthcare stocks that continuously disappointed investors over the years. Though
Johnson & Johnson tumbles on rating downgrade, after opioid ruling
Johnson & Johnson (NYSE: JNJ) continued the slide Wednesday after suffering a big loss in the previous trading session as investor mood
Lannett stock jumps more than 15% after topping Q4 earnings and revenue estimates
Generic drug manufacturer Lannett's (NYSE: LCI) stock surged more than 15% after it reported Q4 earnings results. The company's bottom line and
Why Arbutus Biopharma stock dipped to 11-year low?
Arbutus Biopharma Corporation (NASDAQ: ABUS) stock plunged to an 11-year low of $1.31 on Monday due to considerable downside risk and unsatisfactory
Amgen to take over Celgene’s OTEZLA for $13.4 billion; Bristol-Myers Squibb increases share buyback plan
Bristol-Myers-Squibb (NASDAQ: BMY) announced that Amgen (NASDAQ: AMGN) will acquire Celgene's (NASDAQ: CELG) Otezla business for $13.4 billion in a cash transaction.
Earnings preview: Will losses continue for Celsion in Q2
Celsion Corporation (NASDAQ: CLSN) is set to release its earnings results for the second quarter on Thursday before the market opens. The
Progenics posts wider-than-expected loss in Q2
Progenics Pharmaceuticals (NASDAQ: PGNX) reported a wider loss in the second quarter due to higher costs and expenses despite a jump in
What to look for when Progenics Pharma posts Q2 earnings
Progenics Pharmaceuticals (NASDAQ: PGNX) is set to release its earnings results for the second quarter of 2019 on Friday before the market
Alnylam Pharmaceuticals posts narrower-than-expected Q2 loss
Alnylam Pharmaceuticals (NASDAQ: ALNY) reported a wider loss in the second quarter of 2019 due to higher costs and expenses. The bottom
Immunogen Inc (NASDAQ: IMGN) Q2 2019 Earnings Call Transcript
Immunogen Inc (IMGN) Q2 2019 earnings call dated Aug 02, 2019 Corporate Participants: Courtney O'Konek -- Senior Director of Corporate Communications and Investor Relations Mark